You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAtracurium besylate
Accession NumberDB00732  (APRD00806)
TypeSmall Molecule
GroupsApproved
DescriptionA non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents. [PubChem]
Structure
Thumb
Synonyms
1-[(3,4-Dimethoxyphenyl)methyl]-2-[3-({5-[(3-{1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl}propanoyl)oxy]pentyl}oxy)-3-oxopropyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium
Atracurium besilate
Atracurium dibesylate
External Identifiers
  • BW 33A
  • BW-33A
  • Wellcome 33-A-74
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Atracurium - (for Single Dose )solution10 mgintravenousIvax Pharmaceuticals IncorporatedNot applicableNot applicableCanada
Atracurium - (for Multiple Dose Vial - With Preservative)solution10 mgintravenousIvax Pharmaceuticals IncorporatedNot applicableNot applicableCanada
Atracurium Besylate Injectionliquid10 mgintravenousSandoz Canada Incorporated1998-01-20Not applicableCanada
Atracurium Besylate Injectionliquid10 mgintravenousAbbott Laboratories, Limited1998-02-112007-07-31Canada
Atracurium Besylate Injectionsolution10 mgintravenousHospira Healthcare Corporation1998-07-132012-08-03Canada
Tracriumliquid10 mgintravenousAbbvie Corporation1990-12-312012-11-03Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Atracurium Besylateinjection, solution100 mg/10mLintravenousAurobindo Pharma Limited2015-04-08Not applicableUs
Atracurium Besylateinjection, solution10 mg/mLintravenousHospira, Inc.2012-10-18Not applicableUs
Atracurium Besylateinjection, solution50 mg/5mLintravenousAuro Medics Pharma Llc2015-04-08Not applicableUs
Atracurium Besylateinjection, solution10 mg/mLintravenousHospira, Inc.2012-10-18Not applicableUs
Atracurium Besylateinjection, solution100 mg/10mLintravenousAuro Medics Pharma Llc2015-04-08Not applicableUs
Atracurium Besylateinjection, solution10 mg/mLintravenousSagent Pharmaceuticals2012-05-01Not applicableUs
Atracurium Besylateinjection, solution50 mg/5mLintravenousAurobindo Pharma Limited2015-04-08Not applicableUs
Atracurium Besylateinjection, solution10 mg/mLintravenousSagent Pharmaceuticals2012-05-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII40AX66P76P
CAS number64228-81-5
WeightAverage: 1243.49
Monoisotopic: 1242.500406156
Chemical FormulaC65H82N2O18S2
InChI KeyXXZSQOVSEBAPGS-UHFFFAOYSA-L
InChI
InChI=1S/C53H72N2O12.2C6H6O3S/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6;2*7-10(8,9)6-4-2-1-3-5-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3;2*1-5H,(H,7,8,9)/q+2;;/p-2
IUPAC Name
1-[(3,4-dimethoxyphenyl)methyl]-2-[3-({5-[(3-{1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl}propanoyl)oxy]pentyl}oxy)-3-oxopropyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium dibenzenesulfonate
SMILES
[O-]S(=O)(=O)C1=CC=CC=C1.[O-]S(=O)(=O)C1=CC=CC=C1.COC1=CC2=C(C=C1OC)C(CC1=CC(OC)=C(OC)C=C1)[N+](C)(CCC(=O)OCCCCCOC(=O)CC[N+]1(C)CCC3=C(C=C(OC)C(OC)=C3)C1CC1=CC(OC)=C(OC)C=C1)CC2
Taxonomy
ClassificationNot classified
Pharmacology
IndicationFor use, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
PharmacodynamicsAtracurium is a nondepolarizing skeletal muscle relaxant. Atracurium can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation. The duration of neuromuscular block produced by Atracurium is approximately one third to one half the duration of block by d-tubocurarine, metocurine, and pancuronium at initially equipotent doses. As with other nondepolarizing neuromuscular blockers, the time to onset of paralysis decreases and the duration of maximum effect increases with increasing doses of Atracurium. Repeated administration of maintenance doses of Atracurium has no cumulative effect on the duration of neuromuscular block if recovery is allowed to begin prior to repeat dosing. Moreover, the time needed to recover from repeat doses does not change with additional doses. Repeat doses can therefore be administered at relatively regular intervals with predictable results.
Mechanism of actionAtracurium antagonizes the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. This antagonism is inhibited, and neuromuscular block reversed, by acetylcholinesterase inhibitors such as neostigmine, edrophonium, and pyridostigmine.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeThe elimination half-life is approximately 20 minutes.
ClearanceNot Available
ToxicityExcessive doses can be expected to produce enhanced pharmacological effects. Overdosage may increase the risk of histamine release and cardiovascular effects, especially hypotension.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9907
Blood Brain Barrier+0.9367
Caco-2 permeable+0.6226
P-glycoprotein substrateSubstrate0.8276
P-glycoprotein inhibitor IInhibitor0.5282
P-glycoprotein inhibitor IIInhibitor0.6888
Renal organic cation transporterNon-inhibitor0.5447
CYP450 2C9 substrateNon-substrate0.8354
CYP450 2D6 substrateNon-substrate0.6895
CYP450 3A4 substrateSubstrate0.6913
CYP450 1A2 substrateNon-inhibitor0.9225
CYP450 2C9 inhibitorNon-inhibitor0.9468
CYP450 2D6 inhibitorNon-inhibitor0.8816
CYP450 2C19 inhibitorNon-inhibitor0.9107
CYP450 3A4 inhibitorNon-inhibitor0.8359
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9068
Ames testNon AMES toxic0.7032
CarcinogenicityNon-carcinogens0.9241
BiodegradationNot ready biodegradable0.7843
Rat acute toxicity2.5245 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8459
hERG inhibition (predictor II)Non-inhibitor0.5169
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injection, solutionintravenous10 mg/mL
Injection, solutionintravenous100 mg/10mL
Injection, solutionintravenous50 mg/5mL
Liquidintravenous10 mg
Solutionintravenous10 mg
Prices
Unit descriptionCostUnit
Atracurium 10 mg/ml vial0.96USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point85-90Stenlake, J.B., Waigh, R.D., Dewar,G.H., Urwin, J. and Dhar, N.C.; U.S. Patent 4,179,507 December 18,1979; assigned to BurroughsWellcome Company.
water solubilityMiscibleNot Available
Predicted Properties
PropertyValueSource
Water Solubility4.17e-05 mg/mLALOGPS
logP3.34ALOGPS
logP-0.96ChemAxon
logS-7.5ALOGPS
pKa (Strongest Acidic)19.02ChemAxon
pKa (Strongest Basic)-4.1ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area126.44 Å2ChemAxon
Rotatable Bond Count28ChemAxon
Refractivity280.68 m3·mol-1ChemAxon
Polarizability104.67 Å3ChemAxon
Number of Rings8ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Steven A. Chamberlin, Ashok V. Bhatia, Deborah A. Davis, Keith A. Drengler, “Process for the preparation and isolation of atracurium besylate.” U.S. Patent US5684154, issued September, 1995.

US5684154
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS Codes
  • 12:20.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (162 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with 1,10-Phenanthroline.
4-AndrostenedioneAtracurium besylate may increase the adverse neuromuscular activities of 4-Androstenedione.
AclidiniumAclidinium may increase the anticholinergic activities of Atracurium besylate.
AclidiniumThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Aclidinium.
AlclometasoneAtracurium besylate may increase the adverse neuromuscular activities of Alclometasone.
AldosteroneAtracurium besylate may increase the adverse neuromuscular activities of Aldosterone.
AlfentanilThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Alfentanil.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Alphacetylmethadol.
AmbenoniumThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Ambenonium.
AmcinonideAtracurium besylate may increase the adverse neuromuscular activities of Amcinonide.
AmlodipineAmlodipine may increase the neuromuscular blocking activities of Atracurium besylate.
AmrinoneAmrinone may increase the neuromuscular blocking activities of Atracurium besylate.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Atracurium besylate.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Atracurium besylate.
AzelnidipineAzelnidipine may increase the neuromuscular blocking activities of Atracurium besylate.
AzimilideAzimilide may increase the neuromuscular blocking activities of Atracurium besylate.
BarnidipineBarnidipine may increase the neuromuscular blocking activities of Atracurium besylate.
Beclomethasone dipropionateAtracurium besylate may increase the adverse neuromuscular activities of Beclomethasone dipropionate.
BenactyzineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Benactyzine.
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Atracurium besylate.
BenidipineBenidipine may increase the neuromuscular blocking activities of Atracurium besylate.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Atracurium besylate.
BepridilBepridil may increase the neuromuscular blocking activities of Atracurium besylate.
BetamethasoneAtracurium besylate may increase the adverse neuromuscular activities of Betamethasone.
BezitramideThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Bezitramide.
BiperidenThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Biperiden.
Botulinum Toxin Type AAtracurium besylate may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BAtracurium besylate may increase the anticholinergic activities of Botulinum Toxin Type B.
BudesonideAtracurium besylate may increase the adverse neuromuscular activities of Budesonide.
BuprenorphineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Buprenorphine.
ButorphanolThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Butorphanol.
CarfentanilThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Carfentanil.
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Atracurium besylate.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Chlorphenoxamine.
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Atracurium besylate.
CiclesonideAtracurium besylate may increase the adverse neuromuscular activities of Ciclesonide.
CilnidipineCilnidipine may increase the neuromuscular blocking activities of Atracurium besylate.
CimetropiumAtracurium besylate may increase the anticholinergic activities of Cimetropium.
CinnarizineCinnarizine may increase the neuromuscular blocking activities of Atracurium besylate.
ClevidipineClevidipine may increase the neuromuscular blocking activities of Atracurium besylate.
Clobetasol propionateAtracurium besylate may increase the adverse neuromuscular activities of Clobetasol propionate.
ClocortoloneAtracurium besylate may increase the adverse neuromuscular activities of Clocortolone.
CodeineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Codeine.
Cortisone acetateAtracurium besylate may increase the adverse neuromuscular activities of Cortisone acetate.
CoumaphosThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Coumaphos.
CyclopentolateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Cyclopentolate.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Atracurium besylate.
DarodipineDarodipine may increase the neuromuscular blocking activities of Atracurium besylate.
DecamethoniumThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Decamethonium.
DehydroepiandrosteroneAtracurium besylate may increase the adverse neuromuscular activities of Dehydroepiandrosterone.
dehydroepiandrosterone sulfateAtracurium besylate may increase the adverse neuromuscular activities of dehydroepiandrosterone sulfate.
DemecariumThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Demecarium.
DesfluraneDesflurane may increase the neuromuscular blocking activities of Atracurium besylate.
DesloratadineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Desloratadine.
DesoximetasoneAtracurium besylate may increase the adverse neuromuscular activities of Desoximetasone.
Desoxycorticosterone acetateAtracurium besylate may increase the adverse neuromuscular activities of Desoxycorticosterone acetate.
DexamethasoneAtracurium besylate may increase the adverse neuromuscular activities of Dexamethasone.
Dexamethasone isonicotinateAtracurium besylate may increase the adverse neuromuscular activities of Dexamethasone isonicotinate.
DexetimideThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Dexetimide.
DextromoramideThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Dezocine.
DichlorvosThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Dichlorvos.
DicyclomineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Dicyclomine.
DiflorasoneAtracurium besylate may increase the adverse neuromuscular activities of Diflorasone.
DifluocortoloneAtracurium besylate may increase the adverse neuromuscular activities of Difluocortolone.
DifluprednateAtracurium besylate may increase the adverse neuromuscular activities of Difluprednate.
DihydrocodeineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Dihydromorphine.
DiltiazemDiltiazem may increase the neuromuscular blocking activities of Atracurium besylate.
DiphenoxylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Diphenoxylate.
DonepezilThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Donepezil.
DotarizineDotarizine may increase the neuromuscular blocking activities of Atracurium besylate.
DPDPEThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with DPDPE.
DronabinolAtracurium besylate may increase the tachycardic activities of Dronabinol.
EchothiophateThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Echothiophate.
EdrophoniumThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Edrophonium.
EfonidipineEfonidipine may increase the neuromuscular blocking activities of Atracurium besylate.
EluxadolineAtracurium besylate may increase the constipating activities of Eluxadoline.
EnfluraneEnflurane may increase the neuromuscular blocking activities of Atracurium besylate.
EperisoneEperisone may increase the neuromuscular blocking activities of Atracurium besylate.
EquileninAtracurium besylate may increase the adverse neuromuscular activities of Equilenin.
EquilinAtracurium besylate may increase the adverse neuromuscular activities of Equilin.
EstroneAtracurium besylate may increase the adverse neuromuscular activities of Estrone.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Atracurium besylate.
EthylmorphineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Ethylmorphine.
EtorphineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Etorphine.
FelodipineFelodipine may increase the neuromuscular blocking activities of Atracurium besylate.
FendilineFendiline may increase the neuromuscular blocking activities of Atracurium besylate.
FentanylThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Fentanyl.
FenthionThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Fenthion.
FesoterodineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Fesoterodine.
FludrocortisoneAtracurium besylate may increase the adverse neuromuscular activities of Fludrocortisone.
FlumethasoneAtracurium besylate may increase the adverse neuromuscular activities of Flumethasone.
FlunarizineFlunarizine may increase the neuromuscular blocking activities of Atracurium besylate.
FlunisolideAtracurium besylate may increase the adverse neuromuscular activities of Flunisolide.
Fluocinolone AcetonideAtracurium besylate may increase the adverse neuromuscular activities of Fluocinolone Acetonide.
FluocinonideAtracurium besylate may increase the adverse neuromuscular activities of Fluocinonide.
FluocortoloneAtracurium besylate may increase the adverse neuromuscular activities of Fluocortolone.
FluorometholoneAtracurium besylate may increase the adverse neuromuscular activities of Fluorometholone.
FluprednideneAtracurium besylate may increase the adverse neuromuscular activities of Fluprednidene.
FluprednisoloneAtracurium besylate may increase the adverse neuromuscular activities of Fluprednisolone.
FlurandrenolideAtracurium besylate may increase the adverse neuromuscular activities of Flurandrenolide.
Fluticasone furoateAtracurium besylate may increase the adverse neuromuscular activities of Fluticasone furoate.
Fluticasone PropionateAtracurium besylate may increase the adverse neuromuscular activities of Fluticasone Propionate.
FosphenytoinFosphenytoin may decrease the neuromuscular blocking activities of Atracurium besylate.
GabapentinGabapentin may increase the neuromuscular blocking activities of Atracurium besylate.
GalantamineThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Atracurium besylate.
Ginkgo bilobaThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Ginkgo biloba.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Glucagon recombinant.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Atracurium besylate.
GlycopyrroniumAtracurium besylate may increase the anticholinergic activities of Glycopyrronium.
HalothaneHalothane may increase the neuromuscular blocking activities of Atracurium besylate.
HeroinThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Heroin.
HexamethoniumThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Hexamethonium.
HomatropineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Homatropine.
Huperzine AThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Huperzine A.
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Atracurium besylate.
HydrocodoneThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Hydrocodone.
HydrocortisoneAtracurium besylate may increase the adverse neuromuscular activities of Hydrocortisone.
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Atracurium besylate.
HydromorphoneThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Hydromorphone.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Atracurium besylate.
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Atracurium besylate.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Atracurium besylate.
IsofluraneIsoflurane may increase the neuromuscular blocking activities of Atracurium besylate.
IsoflurophateThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Isoflurophate.
IsradipineIsradipine may increase the neuromuscular blocking activities of Atracurium besylate.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Atracurium besylate.
KetobemidoneThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Ketobemidone.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Atracurium besylate.
LacidipineLacidipine may increase the neuromuscular blocking activities of Atracurium besylate.
LamotrigineLamotrigine may increase the neuromuscular blocking activities of Atracurium besylate.
LercanidipineLercanidipine may increase the neuromuscular blocking activities of Atracurium besylate.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Levomethadyl Acetate.
LevorphanolThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Levorphanol.
LofentanilThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Lofentanil.
Magnesium SulfateMagnesium Sulfate may increase the neuromuscular blocking activities of Atracurium besylate.
MalathionThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Malathion.
ManidipineManidipine may increase the neuromuscular blocking activities of Atracurium besylate.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Atracurium besylate.
MedrysoneAtracurium besylate may increase the adverse neuromuscular activities of Medrysone.
MefloquineThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Mefloquine.
MelengestrolAtracurium besylate may increase the adverse neuromuscular activities of Melengestrol.
MemantineThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Memantine.
MethadoneThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Methadyl Acetate.
MethanthelineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Methantheline.
MethoxyfluraneMethoxyflurane may increase the neuromuscular blocking activities of Atracurium besylate.
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Atracurium besylate.
MethylprednisoloneAtracurium besylate may increase the adverse neuromuscular activities of Methylprednisolone.
MetixeneThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Metixene.
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Atracurium besylate.
MianserinMianserin may increase the anticholinergic activities of Atracurium besylate.
MibefradilMibefradil may increase the neuromuscular blocking activities of Atracurium besylate.
MinaprineThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Minaprine.
MirabegronThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Mirabegron.
MometasoneAtracurium besylate may increase the adverse neuromuscular activities of Mometasone.
MorphineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Morphine.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with N-butylscopolammonium bromide.
NabiloneAtracurium besylate may increase the tachycardic activities of Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Nalbuphine.
NeostigmineThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Neostigmine.
NicardipineNicardipine may increase the neuromuscular blocking activities of Atracurium besylate.
NifedipineNifedipine may increase the neuromuscular blocking activities of Atracurium besylate.
NiguldipineNiguldipine may increase the neuromuscular blocking activities of Atracurium besylate.
NiludipineNiludipine may increase the neuromuscular blocking activities of Atracurium besylate.
NilvadipineNilvadipine may increase the neuromuscular blocking activities of Atracurium besylate.
NimesulideNimesulide may increase the neuromuscular blocking activities of Atracurium besylate.
NimodipineNimodipine may increase the neuromuscular blocking activities of Atracurium besylate.
NisoldipineNisoldipine may increase the neuromuscular blocking activities of Atracurium besylate.
NitrendipineNitrendipine may increase the neuromuscular blocking activities of Atracurium besylate.
Nitrous oxideNitrous oxide may increase the neuromuscular blocking activities of Atracurium besylate.
NormethadoneThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Normethadone.
NVA237The risk or severity of adverse effects can be increased when Atracurium besylate is combined with NVA237.
OpiumThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Opium.
OrphenadrineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Orphenadrine.
OxybutyninThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Oxybutynin.
OxycodoneThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Oxymorphone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Atracurium besylate.
PancuroniumThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Pancuronium.
ParamethasoneAtracurium besylate may increase the adverse neuromuscular activities of Paramethasone.
PentazocineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Pentazocine.
PentoliniumThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Pentolinium.
PerhexilinePerhexiline may increase the neuromuscular blocking activities of Atracurium besylate.
PethidineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Pethidine.
PhenytoinPhenytoin may decrease the neuromuscular blocking activities of Atracurium besylate.
PhysostigmineThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Physostigmine.
PinaveriumPinaverium may increase the neuromuscular blocking activities of Atracurium besylate.
PipecuroniumThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Pipecuronium.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Atracurium besylate.
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Atracurium besylate.
Potassium ChlorideAtracurium besylate may increase the ulcerogenic activities of Potassium Chloride.
PramlintidePramlintide may increase the anticholinergic activities of Atracurium besylate.
PrednicarbateAtracurium besylate may increase the adverse neuromuscular activities of Prednicarbate.
PrednisoloneAtracurium besylate may increase the adverse neuromuscular activities of Prednisolone.
PrednisoneAtracurium besylate may increase the adverse neuromuscular activities of Prednisone.
PregabalinPregabalin may increase the neuromuscular blocking activities of Atracurium besylate.
PregnenoloneAtracurium besylate may increase the adverse neuromuscular activities of Pregnenolone.
PrenylaminePrenylamine may increase the neuromuscular blocking activities of Atracurium besylate.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Atracurium besylate.
PropanthelineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Propantheline.
PyridostigmineThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Pyridostigmine.
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Atracurium besylate.
QuinidineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Quinidine.
RamosetronAtracurium besylate may increase the constipating activities of Ramosetron.
RemifentanilThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Remifentanil.
RimexoloneAtracurium besylate may increase the adverse neuromuscular activities of Rimexolone.
RisedronateRisedronate may increase the neuromuscular blocking activities of Atracurium besylate.
RivastigmineThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Rivastigmine.
ScopolamineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Scopolamine.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Scopolamine butylbromide.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Atracurium besylate.
SevofluraneSevoflurane may increase the neuromuscular blocking activities of Atracurium besylate.
SolifenacinThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Solifenacin.
SpironolactoneSpironolactone may increase the neuromuscular blocking activities of Atracurium besylate.
SufentanilThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Sufentanil.
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Atracurium besylate.
TacrineThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Tacrine.
TapentadolThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Tapentadol.
TiotropiumAtracurium besylate may increase the anticholinergic activities of Tiotropium.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Atracurium besylate.
TixocortolAtracurium besylate may increase the adverse neuromuscular activities of Tixocortol.
Tolfenamic AcidTolfenamic Acid may increase the neuromuscular blocking activities of Atracurium besylate.
TolterodineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Tolterodine.
TopiramateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Tramadol.
TranilastTranilast may increase the neuromuscular blocking activities of Atracurium besylate.
TriamcinoloneAtracurium besylate may increase the adverse neuromuscular activities of Triamcinolone.
TrichlorfonThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Trichlorfon.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Atracurium besylate.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Atracurium besylate.
TrimethaphanThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Trimethaphan.
TropicamideThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Tropicamide.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Atracurium besylate.
TubocurarineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Tubocurarine.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Atracurium besylate.
UmeclidiniumThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Umeclidinium.
VecuroniumThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Vecuronium.
VerapamilVerapamil may increase the neuromuscular blocking activities of Atracurium besylate.
XylometazolineXylometazoline may increase the neuromuscular blocking activities of Atracurium besylate.
ZiconotideZiconotide may increase the neuromuscular blocking activities of Atracurium besylate.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Drug binding
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRNA2
Uniprot ID:
Q15822
Molecular Weight:
59764.82 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Jonsson Fagerlund M, Dabrowski M, Eriksson LI: Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. doi: 10.1097/ALN.0b013e31819fade3. [PubMed:19417616 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23